Mesoblast Limited (MESO)
(Delayed Data from NSDQ)
$15.17 USD
-0.09 (-0.59%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $15.09 -0.08 (-0.53%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
MESO 15.17 -0.09(-0.59%)
Will MESO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MESO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MESO
Mesoblast Limited (MESO) Is Up 40.59% in One Week: What You Should Know
Mesoblast Limited (MESO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
MESO: What are Zacks experts saying now?
Zacks Private Portfolio Services
MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024
MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease
Other News for MESO
12 Health Care Stocks Moving In Friday's Intraday Session
Independent Bank Posts Upbeat Earnings, Joins Blaize Holdings, Interactive Brokers Group And Other Big Stocks Moving Higher On Friday
Mesoblast (MESO) Downgraded by Jefferies to Hold | MESO Stock News
12 Health Care Stocks Moving In Friday's Pre-Market Session
This Elevance Health Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday